Comparative Pharmacology
Head-to-head clinical analysis: DROSPIRENONE ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM versus ESTRACE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROSPIRENONE ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM versus ESTRACE.
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM vs ESTRACE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of drospirenone (a progestin with antimineralocorticoid and antiandrogenic activity), ethinyl estradiol (an estrogen), and levomefolate calcium (a folate supplement). Prevents ovulation by suppressing gonadotropins; increases cervical mucus viscosity, inhibiting sperm penetration; levomefolate provides folate to reduce neural tube defect risk.
Estradiol, a form of estrogen, binds to and activates nuclear estrogen receptors (ERα and ERβ), leading to modulation of gene transcription and subsequent physiological effects including development of secondary sexual characteristics, regulation of reproductive cycle, and effects on bone density, lipid metabolism, and cardiovascular system.
One tablet orally once daily for 28 days (21 active tablets containing drospirenone 3 mg, ethinyl estradiol 0.02 mg, and levomefolate calcium 0.451 mg, followed by 7 placebo tablets containing levomefolate calcium 0.451 mg).
1 to 2 mg orally once daily for continuous estrogen replacement; 0.1% cream applied vaginally 1 to 2 times daily for atrophic vaginitis.
None Documented
None Documented
Drospirenone: ~30 hours (steady state achieved after 8 days). Ethinyl estradiol: ~13-17 hours (biphasic, terminal). Levomefolate calcium: ~4-6 hours (folate derivatives have longer retention).
Terminal half-life: 13-27 hours (mean 19 hours); clinical context: supports once-daily dosing for hormone replacement.
Drospirenone: ~50% renal (as metabolites), ~40% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal. Levomefolate calcium: ~70% renal (as folate metabolites), ~30% fecal.
Renal: 50-80% as glucuronide and sulfate conjugates; fecal: 10-20%; biliary: minor (<5%).
Category D/X
Category C
Progestin + Estrogen
Estrogen